Your browser doesn't support javascript.
loading
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
Villacampa, G; Tung, N M; Pernas, S; Paré, L; Bueno-Muiño, C; Echavarría, I; López-Tarruella, S; Roche-Molina, M; Del Monte-Millán, M; Marín-Aguilera, M; Brasó-Maristany, F; Waks, A G; Pascual, T; Martínez-Sáez, O; Vivancos, A; Conte, P F; Guarneri, V; Vittoria Dieci, M; Griguolo, G; Cortés, J; Llombart-Cussac, A; Muñoz, M; Vidal, M; Adamo, B; Wolff, A C; DeMichele, A; Villagrasa, P; Parker, J S; Perou, C M; Fernandez-Martinez, A; Carey, L A; Mittendorf, E A; Martín, M; Prat, A; Tolaney, S M.
Affiliation
  • Villacampa G; SOLTI Breast Cancer Research Group, Barcelona; Oncology Data Science, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Tung NM; Beth Israel, Boston, USA.
  • Pernas S; Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona.
  • Paré L; Reveal Genomics, Barcelona.
  • Bueno-Muiño C; Medical Oncology Department, Hospital Infanta Cristina (Parla), Fundación de Investigación Biomédica del H.U. Puerta de Hierro, Majadahonda, Madrid.
  • Echavarría I; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid.
  • López-Tarruella S; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid.
  • Roche-Molina M; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid.
  • Del Monte-Millán M; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid.
  • Marín-Aguilera M; Reveal Genomics, Barcelona.
  • Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
  • Pascual T; SOLTI Breast Cancer Research Group, Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Martínez-Sáez O; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Vivancos A; Cancer Genomics Group, VHIO, Barcelona, Spain.
  • Conte PF; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Guarneri V; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Vittoria Dieci M; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Griguolo G; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Cortés J; International Breast Cancer Center, Pangaea Oncology, Quirónsalud Group, Barcelona.
  • Llombart-Cussac A; Arnau de Vilanova Hospital, Universidad Católica de Valencia, Valencia, Spain.
  • Muñoz M; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Vidal M; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Adamo B; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Wolff AC; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore.
  • DeMichele A; Department of Oncology, University of Pennsylvania, Philadelphia.
  • Villagrasa P; Reveal Genomics, Barcelona.
  • Parker JS; Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill.
  • Perou CM; Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill.
  • Fernandez-Martinez A; Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill.
  • Carey LA; Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill.
  • Mittendorf EA; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, USA.
  • Martín M; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid.
  • Prat A; Reveal Genomics, Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Institute of Oncology (IOB)-Quirón, Barcelona, Spain. Elec
  • Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Institute of Oncology (IOB)-Quirón, Barcelona, Spain. Electronic address: sara_tolaney@dfci.harvard.edu.
Ann Oncol ; 34(9): 783-795, 2023 09.
Article in En | MEDLINE | ID: mdl-37302750
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: Spain
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: Spain